Cellceutix Selects Dr. Reddy's for Formulation of Brilacidin

By Supplier News - DCAT Publisher

February 24, 2014

Cellceutix Corporation, a clinical-stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has selected Dr. Reddy's Custom Pharmaceutical Services (CPS), part of the Pharmaceutical Services and Active Ingredients (PSAI) business unit of Dr. Reddy's Laboratories Ltd. for the formulation of the company's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.

Source: Cellceutix